EIC Pavilion at BIO 2026

From 22 to 25 June 2026 the European Innovation Council returned to the BIO International Convention in San Diego. The EIC Pavilion brought fifteen EIC-backed companies from ten European countries to a global biotechnology stage. The pavilion combined a curated exhibition with a programme of panels, investor sessions and reverse pitches aimed at connecting European deep tech and biotech innovators to international investors, corporates and regulators.

Who exhibited and how the roster was presented

The EIC selected fifteen awardees under the International Trade Fairs Programme 3.0 to staff the pavilion. The official account frames the selection as a cross‑section of breakthrough health and biotech solutions. Organisers emphasised that the cohort represented ten European countries and a range of science and technology approaches.

Opening ceremony and high-level participation

The EIC Pavilion opened with a ribbon-cutting ceremony that included senior representatives from the European Commission, the European Medicines Agency and EU Member States. Speakers named in the EIC account included Stéphane Ouaki, Head of the European Innovation Council, Sandra Gallina, Director-General for Health and Food Safety at DG SANTE, and Emer Cooke, Executive Director of the European Medicines Agency. The presence of those officials served to underline the political line that Europe supports innovation-led growth and international engagement in biotechnology.

Programme highlights on the pavilion stage

Organisers ran a programme of thematic panels, investor discussions, reverse pitches and networking events. Panels addressed the intersections of AI and digital biology, the scientific and commercial barriers around first-in-class therapies, precision oncology, and manufacturing and regulatory collaboration. The pavilion also staged reverse-pitch sessions where investors and ecosystem actors summarised partnership priorities and procurement needs to participating companies.

Manufacturing, regulatory collaboration and investor engagement

Panels addressed how advanced manufacturing and early regulatory engagement can shorten timelines and improve scalability. The European Medicines Agency and the European Investment Bank joined discussions with pharmaceutical companies and EIC awardees to map out pathways to market readiness. Parallel reverse-pitch sessions brought institutional and private investors to outline their partnership and licensing priorities. Organisations presenting reverse pitches included the Global Health Investment Corporation, Insight Partners, Johnson and Johnson, and representatives of the Canadian and South Korean ecosystems.

European Night and wider BIO participation

An invitation-only European Night hosted by the EIC and DG SANTE convened representatives from European institutions, national biotech ecosystems, industry, investors and innovators. The event was presented as a platform for transatlantic exchange and to raise the visibility of regional European clusters such as Greece, Catalonia and Switzerland. Beyond the Pavilion, EIC awardees participated in BIO Start-Up Stadium pitching sessions and EIC representatives joined BIO programme discussions on clinical research, regulatory innovation, rare diseases and patient-centred development.

About EIC International Trade Fairs Programme 3.0 and the Pavilion’s purpose

The EIC Pavilion formed part of the EIC International Trade Fairs Programme 3.0. That programme is an instrument of the EIC Business Acceleration Services designed to help European SMEs, scale-ups and start-ups internationalise via curated trade-fair participation, preparatory coaching, matchmaking and onsite support. The public narrative on site focused on visibility, connection building and investor engagement rather than on immediate commercial outcomes.

Assessment and broader context

The EIC Pavilion at BIO 2026 performed the visible work such initiatives are meant to do. It gathered a representative European cohort, generated panels with a mix of technical and policy voices and convened investors and ecosystem partners. That said, public reporting focused on programme activity and stakeholder presence rather than on measurable commercial outcomes. For European innovation policy the important questions are whether participation produces durable partnerships, inward investment or procurement wins and how the EIC will measure and report those conversions.

Practical takeaways for innovators and policymakers

Next steps and where to find more information

Organisers pointed readers to the EIC International Trade Fairs Programme pages and the EIC Business Acceleration Services for open calls and further details. EIC awardees and interested companies can find calls for future trade fairs on the EIC Community Platform. The Pavilion recap was accompanied by a highlight video published by the EIC summarising the week.

The EIC Pavilion at BIO 2026 illustrates the EU’s ongoing effort to put European biotech innovators on the global stage. The real test will be whether this visibility translates into firm, measurable commercial progress for the participating companies and into sustainable transatlantic partnerships that can accelerate patient access to new therapies.